Voyager Therapeutics Inc (NASDAQ:VYGR) has earned a consensus rating of “Buy” from the eleven research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $26.56.

A number of equities research analysts have commented on the stock. BidaskClub upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, August 25th. Robert W. Baird decreased their target price on shares of Voyager Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research note on Thursday, November 8th. Morgan Stanley set a $13.00 target price on shares of Voyager Therapeutics and gave the stock a “hold” rating in a research note on Thursday, November 8th. ValuEngine cut shares of Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Finally, BTIG Research restated a “buy” rating and set a $32.00 target price on shares of Voyager Therapeutics in a research note on Monday, September 10th.

NASDAQ VYGR traded up $0.07 on Friday, reaching $10.73. 252,965 shares of the stock were exchanged, compared to its average volume of 399,309. Voyager Therapeutics has a one year low of $10.31 and a one year high of $31.91. The stock has a market cap of $354.87 million, a price-to-earnings ratio of -4.06 and a beta of 3.07.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Wednesday, November 7th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%. The company had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $3.02 million. Sell-side analysts predict that Voyager Therapeutics will post -2.74 earnings per share for the current fiscal year.

In related news, Director James A. Geraghty acquired 3,000 shares of Voyager Therapeutics stock in a transaction dated Monday, September 10th. The shares were purchased at an average price of $19.39 per share, for a total transaction of $58,170.00. Following the completion of the transaction, the director now directly owns 76,588 shares in the company, valued at approximately $1,485,041.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Glenn Pierce acquired 5,000 shares of Voyager Therapeutics stock in a transaction dated Wednesday, September 12th. The shares were bought at an average price of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. Company insiders own 33.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in VYGR. BB Biotech AG raised its position in shares of Voyager Therapeutics by 27.1% during the second quarter. BB Biotech AG now owns 2,532,641 shares of the company’s stock valued at $49,488,000 after buying an additional 540,000 shares during the last quarter. BlackRock Inc. raised its position in shares of Voyager Therapeutics by 28.3% during the second quarter. BlackRock Inc. now owns 1,845,706 shares of the company’s stock valued at $36,066,000 after buying an additional 407,677 shares during the last quarter. Trustees of Princeton University bought a new stake in shares of Voyager Therapeutics during the second quarter valued at approximately $3,979,000. Vanguard Group Inc. raised its position in shares of Voyager Therapeutics by 10.5% during the third quarter. Vanguard Group Inc. now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after buying an additional 113,442 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $1,929,000. Hedge funds and other institutional investors own 88.57% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Further Reading: Should you buy a closed-end mutual fund?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.